nach oben

Diabetologia

Erschienen in:

01.03.2007 | Article

Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’

verfasst von: M. Lundgren, M. Svensson, S. Lindmark, F. Renström, T. Ruge, J. W. Eriksson

Erschienen in: Diabetologia | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The aim of this study was to explore whether fat cell size in human subcutaneous and omental adipose tissue is independently related to insulin action and adipokine levels.

Materials and methods

Fat cells were prepared from abdominal subcutaneous biopsies obtained from 49 type 2 diabetic and 83 non-diabetic subjects and from omental biopsies obtained from 37 non-diabetic subjects. Cell size and insulin action on glucose uptake capacity in vitro were assessed in isolated fat cells. Insulin sensitivity in vivo was assessed with euglycaemic-hyperinsulinaemic clamps. Fasting blood samples were collected and adipokines and NEFA were measured.

Results

Negative correlations were found between subcutaneous fat cell size and insulin sensitivity assessed as M-value during clamp and as insulin action on glucose uptake in fat cells in vitro. This was seen in non-diabetic subjects after including age, sex and BMI in the analyses. No such relationship was found in type 2 diabetic subjects. In both groups, subcutaneous fat cell size correlated positively and independently with plasma levels of leptin but not to any of the other assessed adipokines. In non-diabetic subjects, omental fat cell size was independently and negatively correlated with insulin action in subcutaneous, but not omental, fat cells in vitro.

Conclusions/interpretation

Fat cell enlargement is associated with insulin resistance in non-diabetic individuals independently of BMI. This was not seen in type 2 diabetic subjects, suggesting that after development of type 2 diabetes other factors, not related to fat cell size, become more important for the modulation of insulin resistance.

Bjorntorp P (1988) Abdominal obesity and the development of noninsulin-dependent diabetes mellitus. Diabetes Metab Rev 4:615–622PubMedCrossRef

Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738PubMedCrossRef

Eriksson JW, Smith U, Waagstein F, Wysocki M, Jansson PA (1999) Glucose turnover and adipose tissue lipolysis are insulin-resistant in healthy relatives of type 2 diabetes patients: is cellular insulin resistance a secondary phenomenon? Diabetes 48:1572–1578PubMed

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE (2000) Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia 43:1498–1506PubMedCrossRef

Buren J, Lindmark S, Renstrom F, Eriksson JW (2003) In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? Metabolism 52:239–245PubMedCrossRef

Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E (1995) A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 38:1213–1217PubMed

Weyer C, Wolford JK, Hanson RL et al (2001) Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21–q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab 72:231–238PubMedCrossRef

Wolford JK, Hanson RL, Bogardus C, Prochazka M (2001) Analysis of the lamin A/C gene as a candidate for type II diabetes susceptibility in Pima Indians. Diabetologia 44:779–782PubMedCrossRef

Danforth E Jr (2000) Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26:13PubMedCrossRef

10.

McGarry JD, Dobbins RL (1999) Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128–138PubMedCrossRef

11.

Shadid S, Jensen MD (2003) Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26:3148–3152PubMed

12.

Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354–1361PubMed

13.

Lonnqvist F, Nordfors L, Jansson M, Thorne A, Schalling M, Arner P (1997) Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 99:2398–2404PubMed

14.

Sopasakis VR, Sandqvist M, Gustafson B et al (2004) High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 12:454–460PubMed

15.

Cinti S, Mitchell G, Barbatelli G et al (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355PubMedCrossRef

16.

Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef

17.

Lukaski HC, Bolonchuk WW, Hall CB, Siders WA (1986) Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol 60:1327–1332PubMed

18.

Eriksson JW, Buren J, Svensson M, Olivecrona T, Olivecrona G (2003) Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 166:359–367PubMedCrossRef

19.

Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW (2004) Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 89:2989–2997PubMedCrossRef

20.

Lindmark S, Buren J, Eriksson JW (2006) Insulin resistance, endocrine function and adipokines in type 2 diabetes patients at different glycaemic levels: potential impact for glucotoxicity in vivo. Clin Endocrinol (Oxf) 65:301–309CrossRef

21.

Smith U, Sjostrom L, Bjornstorp P (1972) Comparison of two methods for determining human adipose cell size. J Lipid Res 13:822–824PubMed

22.

Kashiwagi A, Verso MA, Andrews J, Vasquez B, Reaven G, Foley JE (1983) In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest 72:1246–1254PubMedCrossRef

23.

Lindmark S, Wiklund U, Bjerle P, Eriksson JW (2003) Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first-degree relatives of Type 2 diabetes patients and control subjects. Diabet Med 20:399–405PubMedCrossRef

24.

Graham TE, Yang Q, Bluher M et al (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354:2552–2563PubMedCrossRef

25.

Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB (1993) Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 268:22243–22246PubMed

26.

Boden G (1998) Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 3:169–175

27.

Arner P (2001) Regional differences in protein production by human adipose tissue. Biochem Soc Trans 29:72–75PubMedCrossRef

28.

Segal KR, Landt M, Klein S (1996) Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 45:988–991PubMed

29.

Jansson PA, Eliasson B, Lindmark S, Eriksson JW (2002) Endocrine abnormalities in healthy first-degree relatives of type 2 diabetes patients–potential role of steroid hormones and leptin in the development of insulin resistance. Eur J Clin Invest 32:172–178PubMedCrossRef

30.

Muller G, Ertl J, Gerl M, Preibisch G (1997) Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J Biol Chem 272:10585–10593PubMedCrossRef

31.

Suzuki R, Tobe K, Aoyama M et al (2005) Expression of DGAT2 in white adipose tissue is regulated by central leptin action. J Biol Chem 280:3331–3337PubMedCrossRef

32.

Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–919PubMedCrossRef

33.

Lofgren P, van Harmelen V, Reynisdottir S et al (2000) Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 49:688–692PubMed

34.

Bastard JP, Maachi M, Van Nhieu JT et al (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089PubMedCrossRef

35.

Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784PubMedCrossRef

36.

Gustafson B, Smith U (2006) Cytokines promote Wnt signaling and inflammation and impair the normal differentiation and lipid accumulation in 3T3-L1 preadipocytes. J Biol Chem 281:9507–9516PubMedCrossRef

37.

Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60:349–356PubMedCrossRef

38.

Yang X, Jansson PA, Nagaev I et al (2004) Evidence of impaired adipogenesis in insulin resistance. Biochem Biophys Res Commun 317:1045–1051PubMedCrossRef

39.

Hammarstedt A, Sopasakis VR, Gogg S, Jansson PA, Smith U (2005) Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 48:96–104PubMedCrossRef

40.

Le Lay S, Krief S, Farnier C et al (2001) Cholesterol, a cell size-dependent signal that regulates glucose metabolism and gene expression in adipocytes. J Biol Chem 276:16904–16910PubMedCrossRef

41.

Jernas M, Palming J, Sjoholm K et al (2006) Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. Faseb J 20:1540–1542PubMedCrossRef

42.

Raz I, Eldor R, Cernea S, Shafrir E (2005) Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev 21:3–14PubMedCrossRef

43.

Phillips DI, Caddy S, Ilic V et al (1996) Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism 45:947–950PubMedCrossRef

44.

Krssak M, Falk Petersen K, Dresner A et al (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a ¹H NMR spectroscopy study. Diabetologia 42:113–116PubMedCrossRef

45.

Perseghin G, Scifo P, De Cobelli F et al (1999) Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a ¹H-¹³C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600–1606PubMed

46.

Ryysy L, Hakkinen AM, Goto T et al (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749–758PubMed

Titel: Fat cell enlargement is an independent marker of insulin resistance and ‘hyperleptinaemia’
verfasst von: M. Lundgren
M. Svensson
S. Lindmark
F. Renström
T. Ruge
J. W. Eriksson
Publikationsdatum: 01.03.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 3/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-006-0572-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women

Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome

How much insulin is enough? A quantitative assessment of the transdifferentiaton potential of liver

The long-term impact on offspring of exposure to hyperglycaemia in utero due to maternal glucokinase gene mutations

Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study